Apellis Pharmaceuticals completes $33M private placement of Series C Preferred Stock Apellis Pharmaceuticals, Inc., a respected biotechnology organization applying immunotherapy to autoimmune disease, today announced that it offers completed a $33M private keeping it is Series C Preferred Share. The funding was led by Morningside Ventures and AJU IB Investment Co http://suhagra4ed.com/erectile-dysfunction-treatment.html ., Ltd. With Epidarex Ventures participating with follow-on financing. The proceeds will be used to fund three fresh complement immunotherapy applications entering clinical proof-of-concept stage.


Results of ADVANCE-2 first were in July 2009 at the 22nd Congress of the presented International Culture on Thrombosis and Haemostasis in Boston. Patients undergoing main orthopedic medical procedures, including total knee replacement, are at risky for venous thromboembolism. In fact, venous thromboembolism happens in 40 to 60 % of patients undergoing orthopedic surgery who do not get preventive care. With an estimated 400,000 people world-wide undergoing total knee substitute surgery each year, the threat of venous thromboembolism and its associated morbidity and mortality risk represent an evergrowing challenge to physicians.D., Hoersholm Hospital in Copenhagen, Denmark, lead investigator for the study.? About Bristol-Myers Squibb..

Other articles from category "gastroenterology":

Random articles